Albiglutide

Albiglutide
Clinical data
Trade names	Eperzan (Europe), Tanzeum (US)
Other names	GSK-716155
AHFS/Drugs.com	tanzeum
Routes of; administration	Subcutaneous (SC)
ATC code	A10BJ04 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only;
Pharmacokinetic data
Protein binding	Probably none
Metabolism	Most likely proteolysis
Elimination half-life	5 (4–7) days
Identifiers
CAS Number	782500-75-8;
PubChem SID	96025526;
DrugBank	DB09043;
ChemSpider	none;
UNII	5E7U48495E;
KEGG	D08843;
Chemical and physical data
Formula	C3232H5032N864O979S41
Molar mass	72971.34 g·mol−1

Albiglutide (trade names Eperzan in Europe and Tanzeum in the US) is a glucagon-like peptide-1 agonist (GLP-1 agonist) drug marketed by GlaxoSmithKline (GSK) for treatment of type 2 diabetes. As of 2017 it is unclear if it affects a person's risk of death.^[2] In 2017 GSK announced Albiglutide's withdrawal from the worldwide market for economic reasons, and remaining stocks in the supply chain were effectively depleted by 2018.

^ "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.
^ Liu J, Li L, Deng K, Xu C, Busse JW, Vandvik PO, et al. (June 2017). "Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis". BMJ. 357: j2499. doi:10.1136/bmj.j2499. PMC 5463186. PMID 28596247.

[1] "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.

[2] Liu J, Li L, Deng K, Xu C, Busse JW, Vandvik PO, et al. (June 2017). "Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis". BMJ. 357: j2499. doi:10.1136/bmj.j2499. PMC 5463186. PMID 28596247.

[1]

[2]